NASDAQ:RUBY - Rubius Therapeutics Stock Price, Forecast & News

Rubius Therapeutics trades on the NASDAQ under the ticker symbol "RUBY."

Rubius Therapeutics Inc (NASDAQ:RUBY) released its earnings results on Thursday, November, 14th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.53) by $0.06. During the same period in the previous year, the business earned ($0.42) earnings per share. View Rubius Therapeutics' Earnings History.

Rubius Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, March 26th 2020. View Earnings Estimates for Rubius Therapeutics.

5 Wall Street analysts have issued 12 month price targets for Rubius Therapeutics' shares. Their forecasts range from $4.00 to $40.00. On average, they anticipate Rubius Therapeutics' stock price to reach $25.00 in the next twelve months. This suggests a possible upside of 135.4% from the stock's current price. View Analyst Price Targets for Rubius Therapeutics.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rubius Therapeutics in the last year. There are currently 1 sell rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Rubius Therapeutics.

News articles about RUBY stock have trended very negative on Monday, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Rubius Therapeutics earned a news sentiment score of -3.0 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the immediate future. View News Stories for Rubius Therapeutics.

Some companies that are related to Rubius Therapeutics include Iovance Biotherapeutics (IOVA), Halozyme Therapeutics (HALO), Audentes Therapeutics (BOLD), Acceleron Pharma (XLRN), Denali Therapeutics (DNLI), Momenta Pharmaceuticals (MNTA), Regenxbio (RGNX), Editas Medicine (EDIT), Sangamo Therapeutics (SGMO), Alector (ALEC), Coherus Biosciences (CHRS), Orchard Therapeutics (ORTX), SpringWorks Therapeutics (SWTX), Krystal Biotech (KRYS) and Fate Therapeutics (FATE).

Based on aggregate information from My MarketBeat watchlists, some companies that other Rubius Therapeutics investors own include Sorrento Therapeutics (SRNE), Momo (MOMO), Axsome Therapeutics (AXSM), ChemoCentryx (CCXI), Crispr Therapeutics (CRSP), Dicerna Pharmaceuticals (DRNA), Nektar Therapeutics (NKTR), Progenics Pharmaceuticals (PGNX), Viking Therapeutics (VKTX) and TENCENT HOLDING/ADR (TCEHY).

(RUBY) raised $200 million in an IPO on Wednesday, July 18th 2018. The company issued 9,500,000 shares at $20.00-$22.00 per share. J.P. Morgan, Morgan Stanley, Jefferies and Leerink Partners acted as the underwriters for the IPO.

Rubius Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include Sumitomo Mitsui Trust Holdings Inc. (1.83%), Nikko Asset Management Americas Inc. (1.83%), State Street Corp (0.78%), Millennium Management LLC (0.07%), California Public Employees Retirement System (0.06%) and Barclays PLC (0.03%). Company insiders that own Rubius Therapeutics stock include Christopher L Carpenter, Francis M Cuss, Robert Langer and Torben Straight Nissen. View Institutional Ownership Trends for Rubius Therapeutics.

RUBY stock was sold by a variety of institutional investors in the last quarter, including Barclays PLC. Company insiders that have sold Rubius Therapeutics company stock in the last year include Christopher L Carpenter, Robert Langer and Torben Straight Nissen. View Insider Buying and Selling for Rubius Therapeutics.

RUBY stock was purchased by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., SG Americas Securities LLC, State Street Corp, Millennium Management LLC and California Public Employees Retirement System. View Insider Buying and Selling for Rubius Therapeutics.

Shares of RUBY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of RUBY stock can currently be purchased for approximately $10.62.

Rubius Therapeutics has a market capitalization of $847.48 million. The company earns $-89,190,000.00 in net income (profit) each year or ($2.27) on an earnings per share basis. Rubius Therapeutics employs 142 workers across the globe.View Additional Information About Rubius Therapeutics.

The official website for Rubius Therapeutics is http://www.rubiustx.com/.

Rubius Therapeutics' mailing address is 399 BINNEY STREET SUITE 300, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-679-9600 or via email at [email protected]